Cargando…

Insights into auto-S-fatty acylation: targets, druggability, and inhibitors

Posttranslational S-fatty acylation (or S-palmitoylation) modulates protein localization and functions, and has been implicated in neurological, metabolic, and infectious diseases, and cancers. Auto-S-fatty acylation involves reactive cysteine residues in the proteins which directly react with fatty...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Lu, Tao, Zhipeng, Wu, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637764/
https://www.ncbi.nlm.nih.gov/pubmed/34977571
http://dx.doi.org/10.1039/d1cb00115a
_version_ 1784608811161485312
author Hu, Lu
Tao, Zhipeng
Wu, Xu
author_facet Hu, Lu
Tao, Zhipeng
Wu, Xu
author_sort Hu, Lu
collection PubMed
description Posttranslational S-fatty acylation (or S-palmitoylation) modulates protein localization and functions, and has been implicated in neurological, metabolic, and infectious diseases, and cancers. Auto-S-fatty acylation involves reactive cysteine residues in the proteins which directly react with fatty acyl-CoA through thioester transfer reactions, and is the first step in some palmitoyl acyltransferase (PAT)-mediated catalysis reactions. In addition, many structural proteins, transcription factors and adaptor proteins might possess such “enzyme-like” activities and undergo auto-S-fatty acylation upon fatty acyl-CoA binding. Auto-S-fatty acylated proteins represent a new class of potential drug targets, which often harbor lipid-binding hydrophobic pockets and reactive cysteine residues, providing potential binding sites for covalent and non-covalent modulators. Therefore, targeting auto-S-fatty acylation could be a promising avenue to pharmacologically intervene in important cellular signaling pathways. Here, we summarize the recent progress in understanding the regulation and functions of auto-S-fatty acylation in cell signaling and diseases. We highlight the druggability of auto-S-fatty acylated proteins, including PATs and other proteins, with potential in silico and rationalized drug design approaches. We also highlight structural analysis and examples of currently known small molecules targeting auto-S-fatty acylation, to gain insights into targeting this class of proteins, and to expand the “druggable” proteome.
format Online
Article
Text
id pubmed-8637764
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-86377642021-12-30 Insights into auto-S-fatty acylation: targets, druggability, and inhibitors Hu, Lu Tao, Zhipeng Wu, Xu RSC Chem Biol Chemistry Posttranslational S-fatty acylation (or S-palmitoylation) modulates protein localization and functions, and has been implicated in neurological, metabolic, and infectious diseases, and cancers. Auto-S-fatty acylation involves reactive cysteine residues in the proteins which directly react with fatty acyl-CoA through thioester transfer reactions, and is the first step in some palmitoyl acyltransferase (PAT)-mediated catalysis reactions. In addition, many structural proteins, transcription factors and adaptor proteins might possess such “enzyme-like” activities and undergo auto-S-fatty acylation upon fatty acyl-CoA binding. Auto-S-fatty acylated proteins represent a new class of potential drug targets, which often harbor lipid-binding hydrophobic pockets and reactive cysteine residues, providing potential binding sites for covalent and non-covalent modulators. Therefore, targeting auto-S-fatty acylation could be a promising avenue to pharmacologically intervene in important cellular signaling pathways. Here, we summarize the recent progress in understanding the regulation and functions of auto-S-fatty acylation in cell signaling and diseases. We highlight the druggability of auto-S-fatty acylated proteins, including PATs and other proteins, with potential in silico and rationalized drug design approaches. We also highlight structural analysis and examples of currently known small molecules targeting auto-S-fatty acylation, to gain insights into targeting this class of proteins, and to expand the “druggable” proteome. RSC 2021-08-25 /pmc/articles/PMC8637764/ /pubmed/34977571 http://dx.doi.org/10.1039/d1cb00115a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Hu, Lu
Tao, Zhipeng
Wu, Xu
Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title_full Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title_fullStr Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title_full_unstemmed Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title_short Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
title_sort insights into auto-s-fatty acylation: targets, druggability, and inhibitors
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637764/
https://www.ncbi.nlm.nih.gov/pubmed/34977571
http://dx.doi.org/10.1039/d1cb00115a
work_keys_str_mv AT hulu insightsintoautosfattyacylationtargetsdruggabilityandinhibitors
AT taozhipeng insightsintoautosfattyacylationtargetsdruggabilityandinhibitors
AT wuxu insightsintoautosfattyacylationtargetsdruggabilityandinhibitors